Alkermes - ALKS Stock Forecast, Price & News

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Alkermes in the last year. There are currently 5 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" ALKS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ALKS, but not buy additional shares or sell existing shares.
View ALKS analyst ratings or view top-rated stocks.

8 Wall Street research analysts have issued 1 year price objectives for Alkermes' stock. Their ALKS share price forecasts range from $25.00 to $36.00. On average, they expect the company's share price to reach $30.11 in the next twelve months. This suggests a possible upside of 15.7% from the stock's current price.
View analysts price targets for ALKS or view top-rated stocks among Wall Street analysts.

Alkermes' stock was trading at $26.13 at the beginning of 2023. Since then, ALKS shares have decreased by 0.4% and is now trading at $26.03.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, April 26th 2023.
View our ALKS earnings forecast.

Alkermes plc (NASDAQ:ALKS) announced its earnings results on Thursday, February, 16th. The company reported $0.14 EPS for the quarter, beating the consensus estimate of $0.05 by $0.09. The firm earned $304.70 million during the quarter, compared to analysts' expectations of $289.80 million. Alkermes had a negative net margin of 14.23% and a negative trailing twelve-month return on equity of 3.32%. Alkermes's quarterly revenue was down 6.1% compared to the same quarter last year. During the same period in the prior year, the company posted $0.13 earnings per share.

ETFs with the largest weight of Alkermes (NASDAQ:ALKS) stock in their portfolio include AdvisorShares Psychedelics ETF (PSIL), Harbor Health Care ETF (MEDI), iShares Neuroscience and Healthcare ETF (IBRN), Psyk Etf (PSYK), First Trust NYSE Arca Biotechnology Index Fund (FBT), ALPS Medical Breakthroughs ETF (SBIO), Invesco Dynamic Biotechnology & Genome ETF (PBE) and Putnam BioRevolution ETF (SYNB).

Alkermes issued an update on its FY 2023 earnings guidance on Monday, February, 20th. The company provided earnings per share guidance of 0-$0.23 for the period, compared to the consensus estimate of $0.26. The company issued revenue guidance of $1.13 billion-$1.25 billion, compared to the consensus revenue estimate of $1.17 billion.

119 employees have rated Alkermes Chief Executive Officer Richard F. Pops on Glassdoor.com. Richard F. Pops has an approval rating of 84% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Alkermes investors own include Gilead Sciences (GILD), Netflix (NFLX), Pfizer (PFE), NVIDIA (NVDA), AbbVie (ABBV), Starbucks (SBUX), Intel (INTC), Johnson & Johnson (JNJ) and Tesla (TSLA).

Alkermes trades on the NASDAQ under the ticker symbol "ALKS."

Alkermes' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Sarissa Capital Management LP (5.46%), Renaissance Technologies LLC (3.44%), Hardman Johnston Global Advisors LLC (3.38%), Cibc World Markets Corp (3.09%), Millennium Management LLC (2.09%) and Geode Capital Management LLC (1.85%). Insiders that own company stock include Blair Curtis Jackson, Christian Todd Nichols, Craig C Hopkinson, Craig C Hopkinson, David Joseph Gaffin, David W Anstice, Emily Peterson Alva, Iain Michael Brown, Michael J Landine, Richard F Pops, Shane Cooke and Wendy L Dixon.
View institutional ownership trends.

Shares of ALKS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ALKS stock can currently be purchased for approximately $26.03.

Alkermes (NASDAQ:ALKS) has a market capitalization of $4.28 billion and generates $1.11 billion in revenue each year. The company earns $-158,270,000.00 in net income (profit) each year or ($0.96) on an earnings per share basis.

The company employs 2,280 workers across the globe.

Alkermes' mailing address is 1 BURLINGTON ROAD CONNAUGHT HOUSE, DUBLIN L2, DUBLIN 4. The official website for the company is www.alkermes.com. The company can be reached via phone at (531) 772-8000, via email at investor_relations@alkermes.com, or via fax at 781-890-0524.